REDMOND, WA, December 26, 2023 -- Pattern Computer®, Inc. ("Pattern" or "the Company") today announced that Mark R. Anderson, Chairman and CEO, is scheduled to present at the J.P. Morgan 2024 Healthcare Conference on Thursday, January 11, 2024, at [...]
Grant from Defense Threat Reduction Agency includes purchase of Pattern's ProSpectral research platform REDMOND, WA, November 15, 2023 -- Pattern Computer®, Inc. ("Pattern" or "the Company") today announced that Lawrence Berkeley National Laboratory (LBNL) and Los Alamos National Laboratory (LANL) [...]
Pattern Announces Promising In Vivo Antiproliferative Activity Against High-Grade Serous Ovarian Cancer with Two Novel Drug Combinations REDMOND, WA, June 13, 2023 -- Pattern Computer®, Inc. (Pattern), a leading AI-powered technology company dedicated to advancing innovative treatments for cancer, [...]
Pattern Discovery Engines™ accurately detect increasing number of diseases in 3 seconds using 2 drops of saliva REDMOND, WA, APRIL 6, 2023 -- Pattern Computer®, Inc. (Pattern) is pleased to announce that Cellus Group and Pattern are collaborating to [...]
REDMOND, WA, August 29, 2022 -- Pattern Computer®, Inc. (PCI) is pleased to announce the advancement of three additional combination therapy candidates against High-grade Serous Ovarian cancer beyond the first stage of in vitro studies. In all three cases, the [...]
From GeekWire: "Pattern Computer takes a unique approach to COVID-19 testing. The company analyzes patterns of light that pass through and are absorbed by spit. The test takes only two drops of saliva and reads off a result from the [...]
REDMOND, WA, August 15, 2022 -- Pattern Computer®, Inc. (PCI) and researchers led by a team from University of Washington have, for the first time, demonstrated that the development of subepithelial Infiltrates (SEI) due to conjunctivitis infection can be accurately [...]
REDMOND, WA, May 24, 2022 -- Pattern Computer®, Inc. (PCI) is pleased to announce the advancement of our potential combination therapy candidates against High-grade Serous Ovarian cancer beyond the first stage of in vitro studies. In both cases, the [...]
REDMOND, WA, APRIL 18, 2022 -- Pattern Computer®, Inc. (PCI) is thrilled to announce that our combination drug candidates targeting High-grade Serous Ovarian Cancer (HGSOC) have moved into a preclinical in vitro study. The goal is to evaluate the effectiveness [...]
Pattern Computer Advances Promising Combination Therapy Candidates for Triple-Negative Breast Cancer Through Round Two of Targeted In Vivo Studies REDMOND, WA, APRIL 14, 2022 -- Pattern Computer®, Inc. (PCI) is pleased to announce the advancement of our potential combination therapy [...]
